Dipeptidyl peptidase (DPP-4) inhibitors ("gliptins") are increasingly used in type 2 diabetes mellitus (T2DM) for treating hyperglycaemia. They offer the advantage of improving glucose control without weight gain and with a minimal risk of hypoglycaemia . The study demonstrates that trelagliptin 100 mg once weekly is significantly more effective than placebo and non-inferior to alogliptin 25 mg once
1
. Randomised controlled trials have proven their efficacy and safety as monotherapy in patients on diet and exercise, as dual therapy in add-on to metformin, sulphonylurea, thiazolidinedione or insulin and in various triple therapies 1 . Commercialized DPP-4 inhibitors are used in once-daily administration (sitagliptin, saxagliptin, alogliptin, linagliptin), except vildagliptin that is given twice daily in absence of renal impairment.
Inagaki and colleagues report in the Lancet Diabetes Endocrinology the results of a first 24-week trial comparing the efficacy and safety profile of a once-weekly DPP-4 inhibitor (trelagliptin) with that of the once-daily DPP-4 inhibitor alogliptin in Japanese patients with T2DM treated with diet and exercise 2 . The study demonstrates that trelagliptin 100 mg once weekly is significantly more effective than placebo and non-inferior to alogliptin 25 mg once daily in terms of reduction in glycated haemoglobin (HbA1c). The tolerance/safety profile was good and similar with the two DPP-4 inhibitors. These data should be confirmed in combined therapy, especially in patients not well controlled with metformin 3 . The comparator used in this Japanese study was alogliptin 25 mg whereas, in most comparative studies, the DPP-4 inhibitor used as reference is sitagliptin 100 mg. Although the two once daily DPP-4 inhibitors appear to have a comparable efficacy, no head-to-head trial compared alogliptin and sitagliptin. In a mixed treatment comparison of randomised controlled trials, the weighted absolute HbA1c change from baseline averaged -0.58% (95% confidence interval or CI -0.83, -0.33) with alogliptin and -0.59% (-0.75, -0.43) with sitagliptin 4 . In fact, rather few studies directly compared the efficacy of two different DPP-4 inhibitors 4 . In patients with T2DM
inadequately controlled by metformin alone, saxagliptin 5 mg was noninferior to sitagliptin 100 mg regarding the reduction in HbA1c, although sitagliptin exerted a slightly stronger effect on fasting glucose than saxagliptin 5 , probably because of a more prolonged inhibition of DPP-4 enzyme 6 . Vildagliptin 50 mg twice daily was also associated with a more sustained DPP-4 inhibition over 24 hours, which may contribute to a better control of fasting glucose 
